Health
Results: 997-1008 of 9513

Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting

Medit Establishes Global Orthodontic Business Division, Anchored by Strategic Acquisition of Progressive Orthodontics

SK pharmteco Collaborates with Axle Informatics and the National Institutes of Health to Advance Rare Disease Gene Therapy Programs

FIRST NICE RECOMMENDED TARGETED TREATMENT OPTION FOR ELIGIBLE PATIENTS LIVING WITH UNRESECTABLE LOCALLY ADVANCED STAGE III EGFR-MUTATED LUNG CANCER







